Recent News
June 30, 2026 — FDA granted Rare Pediatric Disease designation for ALXN1840. June 26, 2026 — new analyses from Phase 3 FoCus presented showing neurologic and global clinical benefit for ALXN1840 versus standard of care. July 20–22, 2026 — company expanded commercial leadership and on July 22 initiated a rolling NDA submission for ALXN1840. August 19, 2026 — appointment of an Executive Vice President, Head of Medical Affairs and additional program presentations announced.
Technical Analysis
ADX at 14.61 indicates no clear trend; low ADX suggests price action lacks directional conviction and leaves valuation-sensitive catalysts as primary drivers of moves.
DI+: peak & reversal; that pattern reads bearish for directional strength and favors reduced near-term upside pressure relative to recent highs.
DI-: peak & reversal; that pattern reads bullish for directional weakness but conflicts with DI+ behavior, producing a neutral-to-choppy immediate profile.
MACD: peak & reversal with MACD (1.96) below the signal line (2.64); this alignment signals waning bullish momentum and favors downward drift in short-term momentum.
MRO positive at 18.82; a positive MRO indicates price sits above the model target and implies potential downward mean reversion pressure on the stock.
RSI 58.01 with a peak & reversal signal; the reading sits below overbought levels but the peak-and-reverse suggests diminishing upside impulse.
Price versus moving averages shows price close $112.38 above the 200-day average $75.43, supporting a multi-month premium to long-term trend, while price trades slightly below the 20-day average $113.50 and 12-day EMA $114.68 (12-day EMA trend: peak & reversal), reinforcing a short-term bearish bias inside a longer-term outperforming posture.
Short-term volatility and responsiveness remain elevated: 42-day beta 2.05 and 20-day standard deviation $3.48 with average volume below recent ten- and fifty-day means, suggesting moves can amplify on news-driven flows.
Fundamental Analysis
Liquidity and solvency: cash and short-term investments total $134,298,982 and cash at period end $52,757,766; current ratio 33.56 and cash ratio 33.44, with total current liabilities $4,016,031—liquidity sits at levels that materially reduce near-term refinancing or dilution pressure.
Profitability and operating results: net loss $5,313,300 for the period and operating income (EBIT) negative $6,644,663; research and development expense $4,766,832 continues as the largest operating outflow consistent with a clinical-stage profile. Return on assets -3.89% and return on equity -4.06% reflect ongoing investment into development rather than commercial revenue generation.
Earnings and estimates: reported EPS -$0.62 versus estimate -$0.65, an EPS surprise of +4.62%. Forward EPS -$0.495 and forward PE negative indicate expected continued losses into the forward period; reported PE -148.82 and forward PE -130.43 reflect negative earnings rather than valuation compression relative to peers.
Capital structure and valuation multiples: market cap $619,326,137, enterprise value $485,134,984, and enterprise multiple -73.01. Price/book ratio 4.73 (P/B change QoQ 63.76%, YoY 9.84% when expressed on the provided change metrics). Debt remains negligible: total debt $107,829 and debt-to-equity 0.00082, keeping financial leverage minimal.
Cash flow dynamics: operating cash flow and free cash flow each negative ($3,247,437), free cash flow yield -0.52%, and free cash growth down versus prior periods; cash flow to earnings 61.12% indicates a portion of accounting losses accompanied by cash usage from operations and R&D investment.
Pipeline and corporate-readiness signals: recent regulatory progress for ALXN1840 (Rare Pediatric Disease designation and a rolling NDA submission) plus commercial hires shift valuation focus from preclinical milestones toward regulatory and potential launch-readiness value. The current valuation as determined by WMDST uses a price target mean of $148.86, which implies upside relative to the last close but remains contingent on regulatory outcome and execution.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2026-06-30 |
| REPORT DATE: | 2026-08-12 |
| NEXT REPORT DATE: | 2026-11-11 |
| CASH FLOW | Begin Period Cash Flow | $ 52.5 M |
| Operating Cash Flow | $ -3.25 M | |
| Capital Expenditures | — | |
| Change In Working Capital | $ 1.3 M | |
| Dividends Paid | — | |
| Cash Flow Delta | $ 213.5 K | |
| End Period Cash Flow | $ 52.8 M | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | — | |
| Forward Revenue | — | |
| COSTS | ||
| Cost Of Revenue | — | |
| Depreciation | — | |
| Depreciation and Amortization | — | |
| Research and Development | $ 4.8 M | |
| Total Operating Expenses | $ 6.6 M | |
| PROFITABILITY | ||
| Gross Profit | — | |
| EBITDA | $ -6.64 M | |
| EBIT | $ -6.64 M | |
| Operating Income | $ -6.64 M | |
| Interest Income | $ 1.3 M | |
| Interest Expense | — | |
| Net Interest Income | $ 1.3 M | |
| Income Before Tax | $ -5.31 M | |
| Tax Provision | — | |
| Tax Rate | — | |
| Net Income | $ -5.31 M | |
| Net Income From Continuing Operations | $ -5.31 M | |
| EARNINGS | ||
| EPS Estimate | $ -0.65 | |
| EPS Actual | $ -0.62 | |
| EPS Difference | $ 0.03 | |
| EPS Surprise | 4.615 % | |
| Forward EPS | $ -0.49 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | $ 135.0 M | |
| Intangible Assets | — | |
| Net Tangible Assets | $ 130.9 M | |
| Total Current Assets | $ 134.8 M | |
| Cash and Short-Term Investments | $ 134.3 M | |
| Cash | $ 52.8 M | |
| Net Receivables | — | |
| Inventory | — | |
| Long-Term Investments | — | |
| LIABILITIES | ||
| Accounts Payable | $ 4.0 M | |
| Short-Term Debt | — | |
| Total Current Liabilities | $ 4.0 M | |
| Net Debt | — | |
| Total Debt | $ 107.8 K | |
| Total Liabilities | $ 4.1 M | |
| EQUITY | ||
| Total Equity | $ 130.9 M | |
| Retained Earnings | $ -98.72 M | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | $ 19.50 | |
| Shares Outstanding | 6.712 M | |
| Revenue Per-Share | — | |
| VALUATION | Market Capitalization | $ 619.3 M |
| Enterprise Value | $ 485.1 M | |
| Enterprise Multiple | -73.011 | |
| Enterprise Multiple QoQ | 50.226 % | |
| Enterprise Multiple YoY | 37.486 % | |
| Enterprise Multiple IPRWA | — | |
| EV/R | — | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | 1.032 | |
| Asset To Liability | 32.731 | |
| Debt To Capital | 0.001 | |
| Debt To Assets | 0.001 | |
| Debt To Assets QoQ | -15.789 % | |
| Debt To Assets YoY | -46.309 % | |
| Debt To Assets IPRWA | — | |
| Debt To Equity | 0.001 | |
| Debt To Equity QoQ | -15.464 % | |
| Debt To Equity YoY | -46.753 % | |
| Debt To Equity IPRWA | — | |
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | 4.733 | |
| Price To Book QoQ | 63.759 % | |
| Price To Book YoY | 9.844 % | |
| Price To Book IPRWA | — | |
| Price To Earnings (P/E) | -148.821 | |
| Price To Earnings QoQ | 17.196 % | |
| Price To Earnings YoY | 34.834 % | |
| Price To Earnings IPRWA | — | |
| PE/G Ratio | -4.279 | |
| Price To Sales (P/S) | — | |
| Price To Sales QoQ | — | |
| Price To Sales YoY | — | |
| Price To Sales IPRWA | — | |
| FORWARD MULTIPLES | ||
| Forward P/E | -130.429 | |
| Forward PE/G | -3.75 | |
| Forward P/S | — | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | — | |
| ASSET & SALES | ||
| Asset Turnover Ratio | — | |
| Asset Turnover Ratio QoQ | — | |
| Asset Turnover Ratio YoY | — | |
| Asset Turnover Ratio IPRWA | — | |
| Receivables Turnover | — | |
| Receivables Turnover Ratio QoQ | — | |
| Receivables Turnover Ratio YoY | — | |
| Receivables Turnover Ratio IPRWA | — | |
| Inventory Turnover | — | |
| Inventory Turnover Ratio QoQ | — | |
| Inventory Turnover Ratio YoY | — | |
| Inventory Turnover Ratio IPRWA | — | |
| Days Sales Outstanding (DSO) | — | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | 0.0 | |
| Cash Conversion Cycle Days QoQ | — | |
| Cash Conversion Cycle Days YoY | — | |
| Cash Conversion Cycle Days IPRWA | — | |
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | — | |
| CapEx To Revenue | — | |
| CapEx To Depreciation | — | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | $ 130.9 M | |
| Net Invested Capital | $ 130.9 M | |
| Invested Capital | $ 130.9 M | |
| Net Tangible Assets | $ 130.9 M | |
| Net Working Capital | $ 130.7 M | |
| LIQUIDITY | ||
| Cash Ratio | 33.441 | |
| Current Ratio | 33.556 | |
| Current Ratio QoQ | -40.126 % | |
| Current Ratio YoY | -1.13 % | |
| Current Ratio IPRWA | — | |
| Quick Ratio | — | |
| Quick Ratio QoQ | — | |
| Quick Ratio YoY | — | |
| Quick Ratio IPRWA | — | |
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | -0.016 | |
| Cost Of Debt | 8.354 % | |
| Interest Coverage Ratio | -664.466 | |
| Interest Coverage Ratio QoQ | 27.164 % | |
| Interest Coverage Ratio YoY | 105.444 % | |
| Interest Coverage Ratio IPRWA | — | |
| Operating Cash Flow Ratio | -0.809 | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | — | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | -2.178 % | |
| Revenue Growth | — | |
| Revenue Growth QoQ | — | |
| Revenue Growth YoY | — | |
| Revenue Growth IPRWA | — | |
| Earnings Growth | 34.783 % | |
| Earnings Growth QoQ | -241.452 % | |
| Earnings Growth YoY | -540.57 % | |
| Earnings Growth IPRWA | — | |
| MARGINS | ||
| Gross Margin | — | |
| Gross Margin QoQ | — | |
| Gross Margin YoY | — | |
| Gross Margin IPRWA | — | |
| EBIT Margin | — | |
| EBIT Margin QoQ | — | |
| EBIT Margin YoY | — | |
| EBIT Margin IPRWA | — | |
| Return On Sales (ROS) | — | |
| Return On Sales QoQ | — | |
| Return On Sales YoY | — | |
| Return On Sales IPRWA | — | |
| CASH FLOW | ||
| Free Cash Flow (FCF) | $ -3.25 M | |
| Free Cash Flow Yield | -0.524 % | |
| Free Cash Flow Yield QoQ | -40.991 % | |
| Free Cash Flow Yield YoY | 9.395 % | |
| Free Cash Flow Yield IPRWA | — | |
| Free Cash Growth | -6.519 % | |
| Free Cash Growth QoQ | -311.587 % | |
| Free Cash Growth YoY | -91.949 % | |
| Free Cash Growth IPRWA | — | |
| Free Cash To Net Income | 0.611 | |
| Cash Flow Margin | — | |
| Cash Flow To Earnings | 0.611 | |
| VALUE & RETURNS | ||
| Economic Value Added | — | |
| Return On Assets (ROA) | -3.893 % | |
| Return On Assets QoQ | 39.334 % | |
| Return On Assets YoY | -13.566 % | |
| Return On Assets IPRWA | — | |
| Return On Capital Employed (ROCE) | -5.074 % | |
| Return On Equity (ROE) | -0.041 | |
| Return On Equity QoQ | 41.217 % | |
| Return On Equity YoY | -13.617 % | |
| Return On Equity IPRWA | — | |
| DuPont ROE | — | |
| Return On Invested Capital (ROIC) | — | |
| Return On Invested Capital QoQ | — | |
| Return On Invested Capital YoY | — | |
| Return On Invested Capital IPRWA | — | |